This study aims to explore the efficacy and safety of Erlotinib/Gefitinib combined with bevacizumab in the real world for advanced non-squamous cell lung cancer with EGFR mutation, explore new drug resistance mechanisms under the A+T regimen and consistency between plasma and tissue detection driving genes, and finally assess the predictive value of plasma dynamic detection driving gene mutation profiles in predicting disease. The role of disease progression risk.
Name: Erlotinib/Gefitinib combined with Bevacizumab
Description: Progression free survival
Measure: PFS Time: Approximately 1 yearsDescription: Overall survival
Measure: OS Time: Approximately 1 yearsDescription: Disease control rate
Measure: DCR Time: Approximately 1 yearsCohort
There is one SNP
Inclusion Criteria: - EGFR mutation(19del/L858R) - advanced non-saquamous non-small cell lung cancer - primary treatment of first diagnosis - performance status(0-1) Exclusion Criteria: - other genes mutation - saquamous Inclusion Criteria: - EGFR mutation(19del/L858R) - advanced non-saquamous non-small cell lung cancer - primary treatment of first diagnosis - performance status(0-1) Exclusion Criteria: - other genes mutation - saquamous Non Small Cell Lung Cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung A retrospective study of 30 cases of advanced non-squamous non-small cell lung cancer (NSCLC) with EGFR mutation positive treated with A+T was conducted to observe the efficacy and safety of A+T regimen in the real world. --- L858R ---
Inclusion Criteria: - EGFR mutation(19del/L858R) - advanced non-saquamous non-small cell lung cancer - primary treatment of first diagnosis - performance status(0-1) Exclusion Criteria: - other genes mutation - saquamous Inclusion Criteria: - EGFR mutation(19del/L858R) - advanced non-saquamous non-small cell lung cancer - primary treatment of first diagnosis - performance status(0-1) Exclusion Criteria: - other genes mutation - saquamous Non Small Cell Lung Cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung A retrospective study of 30 cases of advanced non-squamous non-small cell lung cancer (NSCLC) with EGFR mutation positive treated with A+T was conducted to observe the efficacy and safety of A+T regimen in the real world. --- L858R --- --- L858R ---